Impact of local anesthetics on epigenetics in cancer.
cancer
demethylation
epigenetic
local anesthetics
miRNA
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
01
2022
accepted:
01
08
2022
entrez:
16
9
2022
pubmed:
17
9
2022
medline:
17
9
2022
Statut:
epublish
Résumé
Defective silencing of tumor suppressor genes through epigenetic alterations contributes to oncogenesis by perturbing cell cycle regulation, DNA repair or cell death mechanisms. Reversal of such epigenetic changes including DNA hypermethylation provides a promising anticancer strategy. Until now, the nucleoside derivatives 5-azacytidine and decitabine are the sole DNA methyltransferase (DNMT) inhibitors approved by the FDA for the treatment of specific hematological cancers. Nevertheless, due to their nucleoside structure, these inhibitors directly incorporate into DNA, which leads to severe side effects and compromises genomic stability. Much emphasis has been placed on the development of less toxic epigenetic modifiers. Recently, several preclinical studies demonstrated the potent epigenetic effects of local anesthetics, which are routinely used during primary tumor resection to relief surgical pain. These non-nucleoside molecules inhibit DNMT activity, affect the expression of micro-RNAs and repress histone acetylation, thus exerting cytotoxic effects on malignant cells. The in-depth mechanistic comprehension of these epigenetic effects might promote the use of local anesthetics as anticancer drugs.
Identifiants
pubmed: 36110954
doi: 10.3389/fonc.2022.849895
pmc: PMC9468863
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
849895Informations de copyright
Copyright © 2022 Bezu, Kepp and Kroemer.
Déclaration de conflit d'intérêts
OK is scientific co-founder of Samsara Therapeutics. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, Osasuna, PharmaMar, Samsara, Sanofi, Sotio, Vascage and Vasculox/Tioma. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Cell Biochem. 2019 Jun;456(1-2):63-72
pubmed: 30644017
J Thorac Dis. 2018 May;10(5):2804-2812
pubmed: 29997943
Nature. 2005 Jun 9;435(7043):828-33
pubmed: 15944707
Melanoma Res. 2000 Apr;10(2):165-9
pubmed: 10803717
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2866-2874
pubmed: 31299862
BMC Res Notes. 2020 Aug 17;13(1):386
pubmed: 32807213
Cell. 1999 Oct 29;99(3):247-57
pubmed: 10555141
J Pharmacol Sci. 2019 Mar;139(3):186-192
pubmed: 30850243
BMC Cancer. 2019 Mar 15;19(1):233
pubmed: 30876463
Annu Rev Biochem. 2005;74:481-514
pubmed: 15952895
J Cell Biochem. 2019 Oct;120(10):16533-16542
pubmed: 31081972
Front Med (Lausanne). 2022 Jan 13;8:732817
pubmed: 35096852
Br J Anaesth. 2014 Jul;113 Suppl 1:i32-8
pubmed: 24946779
Oncol Rep. 2020 May;43(5):1659-1668
pubmed: 32323811
J Anesth. 2019 Feb;33(1):17-25
pubmed: 30426213
Dig Dis Sci. 2022 Jun;67(6):2244-2256
pubmed: 34050852
Basic Clin Pharmacol Toxicol. 2016 May;118(5):327-32
pubmed: 26525153
Neurotox Res. 2021 Oct;39(5):1440-1448
pubmed: 34115321
Cancers (Basel). 2019 Dec 01;11(12):
pubmed: 31805711
Eur J Pharmacol. 2011 Apr 25;657(1-3):51-8
pubmed: 21315711
Cell Cycle. 2020 Oct;19(19):2530-2537
pubmed: 32892697
Pharmgenomics Pers Med. 2017 May 09;10:157-168
pubmed: 28533693
Pathol Res Pract. 2018 Dec;214(12):1974-1979
pubmed: 30262429
Biol Res. 2019 Jul 12;52(1):36
pubmed: 31300048
Toxicol Res (Camb). 2020 Jul 17;9(4):467-473
pubmed: 32905277
Cancer. 2008 Jun;112(11):2341-51
pubmed: 18398832
Br J Anaesth. 2012 Aug;109(2):200-7
pubmed: 22542536
Oncotarget. 2016 Mar 22;7(12):15262-73
pubmed: 26918830
Anesthesiology. 2006 Oct;105(4):660-4
pubmed: 17006061
BMC Anesthesiol. 2020 Oct 30;20(1):275
pubmed: 33126850
Naunyn Schmiedebergs Arch Pharmacol. 2019 Feb;392(2):123-133
pubmed: 30656360
Front Oncol. 2022 Mar 14;12:772351
pubmed: 35359390
Trends Biochem Sci. 2006 Feb;31(2):89-97
pubmed: 16403636
Clin Epigenetics. 2020 Jun 3;12(1):76
pubmed: 32493461
Acta Anaesthesiol Scand. 2014 Mar;58(3):281-90
pubmed: 24383612
Bioengineered. 2022 Mar;13(3):5975-5986
pubmed: 35191804
Mol Med Rep. 2019 Aug;20(2):1333-1342
pubmed: 31173241
Int J Mol Sci. 2014 Dec 17;15(12):23519-36
pubmed: 25526566
Br J Anaesth. 2006 Nov;97(5):640-6
pubmed: 16952918
J Cancer. 2020 Oct 23;11(24):7312-7319
pubmed: 33193895
Pharmazie. 2017 Nov 1;72(11):663-669
pubmed: 29442040
Histol Histopathol. 2022 May;37(5):461-474
pubmed: 35060113
Dig Dis Sci. 2021 Dec;66(12):4384-4397
pubmed: 33433806
Lancet. 2019 Nov 16;394(10211):1807-1815
pubmed: 31645288
Int J Hematol. 2004 Aug;80(2):128-35
pubmed: 15481440
Med Sci (Paris). 2005 Apr;21(4):405-11
pubmed: 15811306
Lancet Oncol. 2003 Jun;4(6):351-8
pubmed: 12788407
Brain Res Bull. 2021 Dec;177:210-216
pubmed: 34626694
Br J Anaesth. 2018 Oct;121(4):962-968
pubmed: 30236259
Biomed Pharmacother. 2021 Dec;144:112309
pubmed: 34653761
Bioorg Med Chem Lett. 2009 Feb 1;19(3):706-9
pubmed: 19112019
Open Life Sci. 2020 Dec 31;15(1):988-999
pubmed: 33817285
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35483744
PLoS One. 2008 Mar 26;3(3):e1864
pubmed: 18365017
Life Sci. 2020 Jun 15;251:117604
pubmed: 32243929
Bioengineered. 2022 Mar;13(3):6359-6370
pubmed: 35212616
Bioengineered. 2021 Dec;12(1):5231-5240
pubmed: 34414857
Br J Pharmacol. 2015 Jun;172(11):2748-55
pubmed: 25073649
Cancer Manag Res. 2020 Nov 03;12:11145-11155
pubmed: 33173347
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Hepatology. 2020 Jan;71(1):275-290
pubmed: 31188495
Oncol Lett. 2016 Aug;12(2):1164-1170
pubmed: 27446413
Front Pharmacol. 2021 Jun 09;12:681338
pubmed: 34177591
Reg Anesth Pain Med. 2010 Nov-Dec;35(6):490-5
pubmed: 20975461
Anticancer Drugs. 2022 Mar 1;33(3):235-244
pubmed: 35045525
Front Pharmacol. 2021 Sep 21;12:733577
pubmed: 34621169
BMC Anesthesiol. 2020 Feb 21;20(1):43
pubmed: 32085741
Cancer Res. 2003 Nov 15;63(22):7563-70
pubmed: 14633667
Oncol Rep. 2009 Dec;22(6):1479-84
pubmed: 19885602
Anesthesiology. 2008 Aug;109(2):180-7
pubmed: 18648226
Anesthesiology. 2017 May;126(5):868-881
pubmed: 28121635
Exp Mol Med. 2022 Mar;54(3):216-225
pubmed: 35352001
Br J Anaesth. 2015 Nov;115(5):784-91
pubmed: 26475807
Cancer Res. 2003 Aug 15;63(16):4984-9
pubmed: 12941824
Biomed Pharmacother. 2018 Jul;103:823-828
pubmed: 29684861
Nature. 2007 Nov 29;450(7170):736-40
pubmed: 18046414
Front Pharmacol. 2021 May 26;12:681223
pubmed: 34122108
J Cell Biochem. 2018 Feb;119(2):2440-2449
pubmed: 28926119
Hepatol Int. 2007 Sep;1(3):355-64
pubmed: 19669330
Onco Targets Ther. 2020 Jun 09;13:5309-5321
pubmed: 32606749
Cancer Res. 2006 Mar 1;66(5):2794-800
pubmed: 16510601
Oncol Res. 2017 Nov 2;25(9):1463-1470
pubmed: 28251881
Mol Biotechnol. 2022 May;64(5):499-509
pubmed: 34855100
J Pain. 2013 Jan;14(1):36-47
pubmed: 23273833
Aging (Albany NY). 2021 Jun 14;13(12):16341-16352
pubmed: 34126594
J Cell Biochem. 2019 Apr;120(4):6402-6408
pubmed: 30430626
Nurs Res Pract. 2013;2013:961493
pubmed: 24228176
Breast Cancer Res Treat. 2011 Oct;129(3):691-701
pubmed: 21069453
Life Sci. 2019 Sep 1;232:116606
pubmed: 31254586
Am J Transl Res. 2019 Sep 15;11(9):5404-5416
pubmed: 31632519
Nat Med. 2019 Sep;25(9):1428-1441
pubmed: 31501614
J Natl Cancer Inst. 2003 Mar 5;95(5):399-409
pubmed: 12618505
Genet Res Int. 2016;2016:8348450
pubmed: 27843649
Biochem Biophys Res Commun. 2018 Jul 2;501(4):1074-1079
pubmed: 29777701
Aging (Albany NY). 2022 Mar 25;14(6):2793-2804
pubmed: 35333774
Mol Cell Biol. 2004 Feb;24(3):1270-8
pubmed: 14729971
Neuroreport. 2021 Jan 6;32(1):52-60
pubmed: 33252475